Gain Therapeutics (GANX) News Today $2.28 -0.09 (-3.80%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Gain Therapeutics regains compliance with Nasdaq listingJanuary 16, 2025 | msn.comRoth MKM Sticks to Its Buy Rating for Gain Therapeutics (GANX)January 9, 2025 | markets.businessinsider.comGain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287January 9, 2025 | markets.businessinsider.comGain Therapeutics Appoints Gene Mack as Chief Executive Officer and DirectorJanuary 7, 2025 | markets.businessinsider.comGain Therapeutics Appoints Gene Mack As CEOJanuary 7, 2025 | markets.businessinsider.comGain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good ResultsDecember 31, 2024 | seekingalpha.comGain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKMDecember 25, 2024 | markets.businessinsider.comGain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s DiseaseDecember 23, 2024 | markets.businessinsider.comGain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's DiseaseDecember 23, 2024 | globenewswire.comGain Therapeutics To Present At Biotech Showcase 2025December 11, 2024 | globenewswire.comRoth MKM Initiates Coverage of Gain Therapeutics (GANX) with Buy RecommendationDecember 6, 2024 | msn.comPromising Preclinical Data and Financial Position Support Buy Rating for Gain TherapeuticsNovember 26, 2024 | markets.businessinsider.comOptimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 TrialsNovember 21, 2024 | markets.businessinsider.comGain Therapeutics Advances Parkinson’s Therapy DevelopmentNovember 20, 2024 | markets.businessinsider.comGain Therapeutics Receives Buy Rating as GT-02287 Shows Promise for GBA1 Parkinson’s DiseaseNovember 19, 2024 | markets.businessinsider.comGain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate UpdateNovember 15, 2024 | markets.businessinsider.comShort Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 12.6%Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 572,000 shares, a decline of 12.6% from the September 30th total of 654,300 shares. Currently, 2.4% of the shares of the company are short sold. Based on an average daily volume of 387,000 shares, the short-interest ratio is currently 1.5 days.October 29, 2024 | marketbeat.comGain Therapeutics presents data at 36th ENA symposiumOctober 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)October 9, 2024 | markets.businessinsider.comGain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics ConferenceOctober 9, 2024 | markets.businessinsider.comGain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024October 7, 2024 | globenewswire.comGain Therapeutics to Participate at Upcoming Investor ConferencesOctober 3, 2024 | globenewswire.comBTIG maintains Buy rating on Gain Therapeutics sharesOctober 2, 2024 | uk.investing.comBuy Rating Affirmed for Gain Therapeutics’ GT-02287 on Promising Phase 1 Results and Potential in Parkinson’s Disease TreatmentOctober 1, 2024 | markets.businessinsider.comGain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy VolunteersSeptember 30, 2024 | globenewswire.comGain Therapeutics (NASDAQ:GANX) Stock Quotes, Forecast and News SummarySeptember 28, 2024 | benzinga.comGain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's DiseaseSeptember 26, 2024 | globenewswire.comOptimistic Buy Rating for Gain Therapeutics’ GT-02287 Based on Promising Parkinson’s Disease Treatment PotentialSeptember 21, 2024 | markets.businessinsider.comGain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024September 19, 2024 | globenewswire.comBicara, MBX Bio lead gainers as biotech trio makes trading debutSeptember 15, 2024 | msn.comBuy Rating Affirmed for Gain Therapeutics on Promising Phase 1 Results and Solid Financial OutlookSeptember 4, 2024 | markets.businessinsider.comSmall-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's DiseaseAugust 30, 2024 | msn.comGain Therapeutics' GT-02287 For Parkinson's Disease Shows Positive Results In Phase 1 Clinical TrialAugust 29, 2024 | markets.businessinsider.comGain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's DiseaseAugust 29, 2024 | globenewswire.comGene Mack Acquires 14,400 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) StockAugust 13, 2024 | insidertrades.comBuy Rating Affirmed for Gain Therapeutics on GT-02287 Clinical Progress and Robust Financial HealthAugust 10, 2024 | markets.businessinsider.comGain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate UpdateAugust 8, 2024 | globenewswire.comGain Therapeutics to Participate at BTIG Virtual Biotechnology ConferenceAugust 1, 2024 | markets.businessinsider.comGain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's DiseaseJuly 9, 2024 | globenewswire.comGain Therapeutics, Inc. (NASDAQ:GANX) Director Acquires $20,740.00 in StockJuly 2, 2024 | insidertrades.comGain Therapeutics to Hold a Business Update Conference Call on July 1, 2024June 28, 2024 | globenewswire.comGain Therapeutics, Inc. Appoints Gene Mack as Interim CEOJune 27, 2024 | globenewswire.comGain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's diseaseJune 27, 2024 | globenewswire.comGain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceJune 25, 2024 | globenewswire.comWhy Is Gain Therapeutics (GANX) Stock Down 25% Today?June 14, 2024 | investorplace.comGain Therapeutics Announces Pricing of $11.0 Million Public OfferingJune 13, 2024 | globenewswire.comGain Therapeutics Announces Proposed Public OfferingJune 13, 2024 | globenewswire.comGain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024May 30, 2024 | globenewswire.comGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateMay 15, 2024 | finanznachrichten.deBuy Rating Affirmed for Gain Therapeutics Amid Positive Clinical and Financial PerformanceMay 15, 2024 | markets.businessinsider.com Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address GANX Media Mentions By Week GANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GANX News Sentiment▼0.500.44▲Average Medical News Sentiment GANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GANX Articles This Week▼11▲GANX Articles Average Week Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies COMPASS Pathways News Fulcrum Therapeutics News SOPHiA GENETICS News Larimar Therapeutics News Aurora Cannabis News 4D Molecular Therapeutics News Ocugen News Amylyx Pharmaceuticals News Molecular Partners News Acelyrin News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GANX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GANX Stock Alerts